Retatrutide (CAS 2381089-83-2) is a synthetic triple agonist peptide studied for its interaction with GIP, GLP-1, and glucagon receptor pathways simultaneously, distinguishing it from single or dual-receptor agonist peptides. PhaseOne supplies Retatrutide to researchers across Australia as a high-purity lyophilised powder, independently HPLC verified at ≥98% purity per batch.
As one of the newer triple-agonist research peptides, Retatrutide is manufactured to research-grade standards with full third-party testing, shipped Australia-wide across all available strengths. (!) Full Certificate of Analysis available for every batch view here.
Retatrutide is a synthetic triple agonist peptide, studied within Australian peptide research for its simultaneous activity at GIP, GLP-1, and glucagon receptors.
Unlike single-receptor agonists, triple agonist peptides like Retatrutide engage multiple metabolic receptor pathways at once, making them a distinct focus within current research peptide literature.
Retatrutide is supplied in 5mg, 10mg, 15mg, 20mg, and 30mg vials, all shipped Australia-wide with full batch documentation.
Unreconstituted Retatrutide should be stored refrigerated and protected from light, and is commonly reconstituted with bacteriostatic water prior to research preparation. (!) Read our reconstitution guide.
Each PhaseOne batch is independently verified by third-party HPLC analysis, with a Certificate of Analysis available for every order shipped across Australia.
Yes - PhaseOne provides a peptide dosage calculator researchers can use as a reference tool when planning reconstitution and dilution. (!) Use our peptide dosage calculator.
Disclaimer
All products supplied by PhaseOne are intended strictly for laboratory research purposes only. Products are not intended for human consumption, therapeutic use, cosmetic use, veterinary use, or diagnostic applications.
